electroCore welcomes the recent NIHR technology alert on gammaCore, which profiles the CE-marked device’s role in helping patients in the UK manage long-term neurological conditions such as migraine and medically unexplained symptoms. The alert, which is designed to notify clinicians and those involved in the commissioning of healthcare products or services of the availability of new technologies, highlights the potential for gammaCore to enhance the quality of life for people with long-term conditions, thereby aligning with this domain within the NHS Outcomes Framework.
Based upon independent research funded by the NIHR, and published within the NIHR’s Horizon Scanning Research and Intelligence Centre (HSRIC), this alert bolsters the Company’s belief in the potential of gammaCore to help alleviate some of the unique pressures that exist within the UK’s healthcare system. By empowering patients to safely and effectively self-manage their medically unexplained symptoms at home, it is anticipated that usage of the device will help to reduce the workload demand currently placed on GPs and the wider health and social care system.
gammaCore received its first CE mark in 2011, and a positive review from the Interventional Procedures Advisory Committee of the National Institute for Health and Care Excellence (NICE), on its role in the prevention and acute treatment of migraine and cluster headache in April 2016.
The NIHR technology alert can be accessed via the following link: http://www.hsric.nihr.ac.uk/topics/gammacore-for-the-treatment-of-medically-unexplained-symptoms/